The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2827-2839

  Ibuki, Naokazu ^a,b   Ghaffari, Mazyar ^a,c   Reuveni, Hadas ^d,e   Pandey, Mitali ^a   Fazli, Ladan ^a   Azuma, Haruhito ^b   Gleave, Martin E ^a,c   Levitzki, Alexander ^e   Cox, Michael E ^a,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d TyrNovo Ltd   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOCETAXEL; INSULIN RECEPTOR SUBSTRATE; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C; TYRPHOSTIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; IRS1 PROTEIN, HUMAN; IRS2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; TAXOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LNCAP CELL LINE; MALE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ANIMAL; CELL CYCLE CHECKPOINT; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; ORCHIECTOMY; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MICE; ORCHIECTOMY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEOLYSIS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TAXOIDS; TUMOR BURDEN; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918594975     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0842     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006;95:767-74.
3. Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place intherapy. Clin Ther 2006;28:1485-508.
4. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010;291:1-13.
5. Schayek H, Bentov I, Sun S, Plymate SR, Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res 2010;316:1479-88.
6. Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 2011;344:1-24.
7. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-8.
8. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
9. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005;11:52-5.
10. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007;25:134-40.
11. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14.
12. Shaw LM. The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 2011;10:1750-6.
13. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991;352:73-7.
14. White MF, Yenush L. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol 1998;228:179-208.
15. Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, et al. Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. J Biol Chem 1998;273:15719-26.
16. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 2006;66:5304-13.
17. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002;283:E413-22.
18. Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996;56:3391-4.
19. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004;279:5017-24.
20. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 2013;73:4383-94.
21. Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 2000;44:156-63.
22. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
23. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, et al. Upregulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005;36:1186-96.
24. Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, Schiff SC, et al. Irs2 inactivation suppresses tumor progression in Pten+/- mice. Am J Pathol 2009;174:276-86.
25. Boura-Halfon S, Zick Y. Serine kinases of insulin receptor substrate proteins. Vitam Horm 2009;80:313-49.
26. Fritsche L, Neukamm SS, Lehmann R, Kremmer E, Hennige AM, Hunder-Gugel A, et al. Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907. Am J Physiol Endocrinol Metab 2011;300:23.
27. Porter HA, Carey GB, Keegan AD. Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death. Exp Cell Res 2012;318:1745-58.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
30. Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011;71:5754-64.
31. Huang SP, Bao BY, Hour TC, Huang CY, Yu CC, Liu CC, et al. Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. PLoS ONE 2012;7:e41219.
32. Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhofer T, et al. Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS ONE 2012;7:e50953.
33. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8:871-8.
34. Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 2004;59:115-9.
35. Geck P, Maffini MV, Szelei J, Sonnenschein C, Soto AM. Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci U S A 2000;97:10185-90.
36. Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, et al. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000;19:2687-94.
37. Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, et al. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. Prostate Cancer Prostatic Dis 2013;16:239-47.
38. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-15.
39. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620-9.
40. Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 2011;71:525-37.
41. Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP, et al. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2010;70:206-18.
42. Gleave ME, Cox ME, Wang Y. Cell biology of prostate cancer and molecular targets. In:Figg WD, Chau CH, Small EJ, editors. Drug management of prostate cancer. New York, Dordrecht, Heidelberg, London: Springer; 2010. p. 1-26.
43. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68:8322-32.
44. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389-97.
45. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25:6113-22.